Biopharma stock indexes experienced significant corrections in 2018, with high valuations quickly followed by sudden dips. Still, moving into the new year, M&A dealmaking jumped out of the gate with several multi-billion dollar deals in early 2019, according to Syneos.
The company will be presenting the Dealmakers' Intentions: 2019 Market Outlook report during BIO International next week in Philadelphia, PA. The survey, in its 11th year, included responses from more than 150 industry executives and business development professionals.
“Dealmaking in the life sciences industry got off to a strong start in Q1 2019, despite a steep market decline in the last quarter of 2018 and a government shutdown,” said Neel Patel, senior managing director, Syneos Health Consulting and author of the 2019 Dealmakers’ Intentions Study.
Consequently, Patel told us: "2019 is on a path to be one of the strongest dealmaking years of the last decade."
At the BIO Super Session, Patel will be moderating the conversation, with panelists from Wells Fargo, Boston Pharmaceuticals, Eli Lilly and Company, and Roche, among others.
The discussion will set its sights to the next 12 months and address biopharmaceutical dealmakers’ intentions around licensing and acquisitions. It will also identify the areas of greatest opportunity for both buyers and sellers.
“For the first time, this year,” Patel added, “the survey also assessed company interest specifically in orphan drug opportunities, both in terms of the overall level of interest among dealmakers and by therapeutic area.”
The report, not currently released, also will cover “the top 10 hottest areas for licensing.”
Patel said these include, “technologies that have started to gain in prominence, shed light on the therapeutic areas that have fallen in and out of favor and reveal the next hot spot with commercial value.”
